AbbVie Inc. (ABBV)
ABBV moved a median of 0.00% 30 minutes after news, and +0.10% by the close. How ABBV actually reacts to news — the realized, point-in-time move the market made, measured across 731 labeled events over the last three years with zero look-ahead.
ABBV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.01% | 49% | 728 |
| 30-min | 0.00% | 50% | 729 |
| 60-min | +0.11% | 54% | 729 |
| to close | +0.10% | 52% | 727 |
| Middle 50% of ABBV reactions | -0.35% to +0.53% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 731 |
Half of all AbbVie Inc. news events land between -0.35% and +0.53% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ABBV reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 47 | +0.20% | 57% | +0.14% |
| Analyst downgrades | 24 | -0.01% | 50% | +0.45% |
| Coverage initiations | 34 | -0.28% | 41% | -1.03% |
| Rating reiterations | 161 | +0.03% | 52% | +0.07% |
| Price-target raises | 65 | +0.12% | 60% | +0.09% |
| Price-target cuts | 11 | +0.00% | 55% | -0.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ABBV ranks against every other measured name →
That’s how ABBV usually reacts — get an email when it moves on news →Email me when ABBV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABBV's baseline. Nothing else.
Recent ABBV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K AbbVie Inc. For: Oct 14 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease | Press release | PR Newswire | -0.09% | +0.01% | |
| New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease | Press release | PR Newswire | -0.14% | +1.25% | |
| AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC | Press release | PR Newswire | +0.76% | +1.10% | |
| AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma | Press release | PR Newswire | +0.12% | +0.59% | |
| Form 8-K AbbVie Inc. For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | -0.20% | -0.39% | |
| AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo | Press release | PR Newswire | -0.14% | -0.56% | |
| AbbVie to Host Third-Quarter 2026 Earnings Conference Call | Press release | PR Newswire | +0.01% | -0.22% | |
| AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 | Press release | PR Newswire | +0.11% | -1.14% | |
| AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026 | Press release | PR Newswire | +0.11% | -1.14% | |
| AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress | Press release | PR Newswire | +0.11% | -1.14% | |
| AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development | Press release | PR Newswire | +0.80% | -0.81% | |
| U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease | Press release | PR Newswire | +0.42% | +0.74% | |
| EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma | Press release | Canada Newswire | +0.25% | -0.09% | |
| AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis | Press release | PR Newswire | +0.10% | +0.80% | |
| Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach | Press release | PR Newswire | +0.10% | +0.80% | |
| AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery | Press release | PR Newswire | +0.30% | +0.51% | |
| AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026 | Press release | PR Newswire | +0.98% | +0.25% | |
| AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting | Press release | PR Newswire | -0.13% | +0.54% | |
| Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications | Press release | PR Newswire | -0.13% | +0.54% | |
| AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum | Press release | Canada Newswire | -0.29% | +1.20% | |
| AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign | Press release | PR Newswire | -0.29% | +1.20% | |
| Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit | Press release | PR Newswire | -0.29% | +1.20% | |
| AbbVie Declares Quarterly Dividend | Press release | PR Newswire | +0.05% | +0.92% | |
| AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine | Press release | PR Newswire | +0.88% | +1.50% | |
| AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma | Press release | PR Newswire | -0.45% | -1.44% | |
| AbbVie Completes Acquisition of Apogee Therapeutics | Press release | PR Newswire | -0.45% | -1.44% | |
| AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference | Press release | PR Newswire | -0.45% | -1.44% | |
| Form 8-K AbbVie Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | -1.44% | |
| Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care | Press release | PR Newswire | -0.19% | -0.37% | |
| SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings | Press release | PR Newswire | +0.05% | -0.38% | |
| AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference | Press release | PR Newswire | -0.47% | +0.89% | |
| AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease | Press release | PR Newswire | -0.32% | -1.02% | |
| AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline | Press release | PR Newswire | +0.73% | +1.63% | |
| AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support | Press release | PR Newswire | +0.16% | +1.83% | |
| Form 8-K AbbVie Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -0.17% | +1.25% | |
| Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices | Press release | PR Newswire | +0.04% | +0.79% | |
| Form 8-K AbbVie Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | -2.08% | |
| Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence | Press release | PR Newswire | -0.96% | -1.19% | |
| UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment | Press release | Canada Newswire | -0.96% | -1.19% | |
| Form 10-Q AbbVie Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.10% | -0.56% | |
| AbbVie Reports Second-Quarter 2026 Financial Results | Press release | PR Newswire | +2.51% | +1.59% | |
| Form 8-K AbbVie Inc. For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | +2.51% | +1.59% | |
| JUVÉDERM® Day Returns to U.S. on August 19 | Press release | PR Newswire | +1.31% | +0.63% | |
| AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo | Press release | PR Newswire | -0.09% | -0.34% | |
| AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata | Press release | PR Newswire | -0.09% | -0.34% | |
| Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients | Press release | PR Newswire | +0.23% | -1.04% | |
| SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development | Press release | PR Newswire | -0.43% | -0.49% | |
| AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma | Press release | PR Newswire | -0.02% | -0.67% | |
| Form 8-K AbbVie Inc. For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -0.98% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABBV section they belong to.
Where else ABBV is measured.
ABBV earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AIMMUNE THERAPEUTICS (AIMT) | 734 | -0.29% | 40% |
| Vertex Pharmaceuticals Incorporated (VRTX) | 733 | +0.10% | 55% |
| INSYS THERAPEUTICS (INSY) | 731 | +0.00% | 50% |
| Myovant Sciences Ltd. Common Shares (MYOV) | 728 | 0.00% | 49% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is AbbVie Inc.'s median reaction calculated?
Every labeled ABBV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 731 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of ABBV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ABBV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.